We are live on ! Find out more

Abeona Therapeutics

ABEO

Market cap $338M

5.91 USD

-0.13

2.15%

At close Updated Aug 28, 3:07 PM EDT

1 day

-2.15%

5 days

-3.43%

1 month

-1.83%

3 months

2.25%

6 months

16.8%

Year to date

11.3%

1 year

-14.1%

5 years

-81.53%

10 years

-94.37%

About: Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Employees: 226

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 8.3%

Neutral 83.3%

Negative 8.3%

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity

Abeona Therapeutics reported Q2 revenues of $11.4m, treating five Zevaskyn patients, but missed analyst expectations, leading to a 14% stock drop. Operational setbacks in Zevaskyn's rollout, including cancellations and manufacturing issues, highlight a steep learning curve, but management expects improvement as experience grows. Partnered programs with Ultragenyx and Taysha offer potential near-term catalysts, with milestone and royalty payments possible if approvals and sales targets are met.

Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity

Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Abeona Therapeutics Q2 Earnings Call Highlights

Abeona Therapeutics NASDAQ: ABEO reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition.

Abeona Therapeutics Q2 Earnings Call Highlights

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - Expanding QTC network now includes seven sites nationwide; growing number of QTCs progressing patients through treatment process – - $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 – CLEVELAND, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2026 and provided an update on commercial execution for ZEVASKYN (prademagene zamikeracel). Commercial Update Steady launch-year growth for ZEVASKYN.

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its financial results for the second quarter of 2026 and provide a corporate update.

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. NTAP status provides supplemental CMS reimbursement above standard hospital payments to support access to innovative therapies like ZEVASKYN.

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)

NEW YORK, July 27, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Abeona Therapeutics Inc. (NASDAQ: ABEO) on behalf of the company's shareholders. The investigation seeks to determine whether Abeona Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children's as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN ® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). “Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC.

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

See News Rankings

Price charts implemented using Lightweight Charts™